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Poly[d(G-m5C)] was modified by reductively activated mitomycin
C, an anti-tumour drug, under buffer conditions which are
known to favour either the B or the Z conformations of DNA.
C.d. and 31P-n.m.r. were used to characterize the poly[d(G-
m5C)]-mitomycin cross-linked complexes, as well as the effects
on the equilibrium between the B and Z forms of the poly-
nucleotide. Mitomycin C appears to inhibit the B -+ Z transition,
INTRODUCTION
Mitomycin C is widely used in the treatment of a variety of
tumours [1,2]. Among its most interesting properties is the ability
to bind covalently to DNA, resulting in the formation of cross-
links between the complementary strands through bifunctional
alkylation [3-7]. Mitomycin C (Figure 1) is peculiar in that it
needs a reductive activation to react with DNA. The enzymic or
chemical reduction induces an opening of the aziridine ring of the
molecule. Mitomycin is known to bind to DNA with cross-link
formation favoured over monoalkylation on reductive activation
with sodium dithionite [7]. A striking feature is that the drug is
covalently linked exclusively to guanine residues. The bases are
linked at their N-2 positions to mitomycin at its C-1 and C-10
atoms [6]. Numerous results suggest that the cytotoxic action of
mitomycin is related to its capacity to interact with cellular
DNA. Even though the formation of cross-linked adducts has
been described as the cause of the lethal effect on the transformed
cells, recent studies indicate that some chemical derivatives of
mitomycin which are incapable of forming DNA crosslinks also
present anti-tumour effects [8].
DNA regions containing CpG sequences, and thus potential
sites for the formation of mitomycin adducts, have been shown
to be associated with many tissue-specific genes and may rep-
resent regulatory regions in several of these genes [9]. There are
a number of reasons for believing that alterations in the pattern
of methylation (m5C) in CpG tracts are related to the activation/
inhibition of cellular growth and could also promote the carcino-
genic process. The conversion of DNA from the B to the Z
conformation has been studied in many systems [10], and it has
been shown that methylated CpG regions can favour the presence
of Z-DNA under biological conditions [10,11]. In fact, the level
of transcription of the c-myc oncogene is unambiguously associ-
ated with the formation ofZ-DNA in discrete regions of the gene
[11], and it is, therefore, of interest to determine whether
mitomycin and other drugs involved in cancer therapeutics might
interfere with the B Z transition in DNA. In general, this
appears to be the case [12-15], but the precise characteristics of
the mechanism involved are far from being completely under-
stood. It is of interest to study the mitomycin C interaction with
the B and Z forms ofDNA, since it is possible to obtain adducts
of irreversible bifunctionately cross-linked drug by using well-
determined experimental techniques [7], while the use of
even in the presence of 3 mM MgCl2, while the Z-form of
poly[d(G-m5C)] does not interact significantly with the drug
under bifunctionally activating conditions; thus no reversion
from the Z-form to the B-form of the polynucleotide can be
observed under the salt conditions which are required for the
Z-form to exist.
poly[d(G-m5C)] ensuires that the conformational transitions take
place at physiological ionic strength. On the other hand, the
effect of mitomycin C on the B -. Z transition was previously
characterized using other polynucleotides, producing misleading
results [7,16]. At present, it seems fully accepted that mitomycin
C binds to B-DNA but not to Z-DNA [7,17,18], while the
inversion of the c.d. spectra in the presence of cross-linked
mitomycin (see the Z-like spectra in Figure 2a) can be due to
induced c.d. effects as a result of electronic interaction between
the bases and the cross-linked drug [17].
In the present study we analysed the equilibrium between B
and Z forms of poly[d(G-m5C)] and the effect exerted by the bis-
adducts ofmitomycin C on m5CpG bases by using 3UP-n.m.r. and
c.d. spectroscopic approaches on mitomycin cross-linked to
poly[d(G-m5C)].
MATERIALS AND METHODS
Poly[d(G-m5C)] was purchased from Pharmacia-Iberica. Mito-
mycin C was obtained from Boehringer Mannheim. Poly[d(G-
m5C)] was dissolved by rotational mixing at 4 °C for about 16 h
in 25 mM Pipes (pH 7.0)/50 mM NaCl (Buffer B). When
required, MgCl2 was added to 3 mM (Buffer Z) in order to
obtain the Z-conformation of the polynucleotide. All the samples
were dialysed against a large volume of the required buffer, and
sonicated under a nitrogen stream (2 min at 0 °C) in order to
reduce the viscosity.
Treatment of poiy[d(G-m5C)J with mitomycin C under reductive
bifunctional activating conditions
A solution containing 3.5 mM (in nucleotides) of sonicated
poly[d(G-m5C)] and different amounts of a mitomycin C stock
solution were mixed to obtain different ratios ofadded mitomycin
C to nucleotide between 0.5 and 3 in either Buffer B or Buffer Z,
and deaerated by purging with both nitrogen and argon. Sodium
dithionite (Na2S204) was added to the mixture as described
elsewhere [7]. When required, separation of unbound mitomycin
was accomplished by dialysis [4] against Buffer B, or Buffer Z for
experiments performed under Z-forming conditions.
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Figure 1 Molecular structure of mitomycin C
Determination of the mitomycin C to nucleotide-binding ratios
Binding ratios were determined as described in [19]. An 6254
value of 8400 M-1 (nucleotide) cm-' for poly[d(G-m5C)] and an




displays the mitomycin C to nucleotide-binding ratio for some of
the complexes used.
C.d. measurements
C.d. measurements were performed in 1- and 0.05-cm-path-
length cells (the latter cells allowed us to measure c.d. spectra of
samples taken directly from n.m.r. tubes) using a Jasco J-720
spectropolarimeter interfaced to a Hewlett-Packard Vectra
386/25 computer. The temperature was kept constant (25 °C).
The wavelengths scanned ranged from 220 to 400 nm. Scans
were recorded at 1 nm intervals, and two spectra of each sample
were recorded and averaged. A scan of buffer alone was recorded
to provide a baseline. Molar ellipticities {[O] (M-1 - cm-')} were
calculated per nucleotide residue.
3'P-n.m.r. spectroscopy
31p n.m.r. was registered with a Varian Unity 300 (31p,
121.4 MHz) equipped with an HFPC four nucleus probe and
using special low-volume n.m.r. tubes with bulk magnetic sus-
240 380 240
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Figure 2 Effects of bifunctionally activated mitomycin C on the c.d. of poly[d(G-m5C)]
(a) C.d. of the polynucleotide ( ) in Buffer B (25 mM Pipes (pH 7.0)/50 mM NaCI) and in the presence of reductively activated mitomycin C at the following ratios of added drug to nucleotide:
0.5 (. ); 1 (-.-.); and 3 (----). (b) C.d. of the polynucleotide ( ) in Buffer Z [25 mM Pipes (pH 7.0)/50 mM NaCI/3 mM MgCt2] and in the presence of mitomycin C at the
following ratios of added drug to nucleotide: 0.5 (. ); 1 and 3 (----).
Table 1 Preparation and some characteristics of the Poly[d(G-m5C)J-mitomycin C complexes used In the experiments
Molar ratio (ra) Binding ratio (rb) Conformation indicated by:
(mol of drug added! (mol of drug/
Sample mol of nucleotide) mol of nucleotide) C.d. spectrum 31P-n.m.r.
Poly[d(G-m5C)] (B-form)
plus mitomycin C, in Buffer B*
Poly[d(G-m5C)] (B-form)
plus mitomycin C, in Buffer Zt
Poly[d(G-m5C)] (Z-form)
plus mitomycin C, in Buffer B
Poly[d(G-m5C)] (Z-form)















* Buffer B, 25 mM Pipes (pH 7.0)/50 mM NaCI.
t Buffer Z, 25 mM Pipes (pH 7.0)/50 mM NaCI/3 mM MgCI2.
t This spectrum might be due to a drug-induced c.d. spectrum (see the text).
Mitomycin C binding to Poly[d(G-m'C)] 187
ceptibility equal to those for solvent (water/2H20, 1:10). The
samples of the polynucleotide solution in either B or Z con-
formation and the corresponding amount of added mitomycin
(about 0.30 ml final volume) were flushed with argon to avoid the
interference of oxygen with sodium dithionite. The main ac-
quisition and processing parameters were as follows: pulse width,
500, acquisition time = 1 s, recycle time = 1.5 s, spectral
window = 3000 Hz, Waltz 'H decoupling, line broadening =
5 Hz and Fourier transform points = 16384. All spectra were
acquired overnight (number of transitions = 40000) at 25 'C.
Chemical shifts (a) are given in p.p.m. and referenced externally
against trimethyl phosphate acquired in the same conditions as
the sample (ZO, lock field and shim values) to avoid inconsist-
encies in the reference.
RESULTS
C.d. studies
Figure 2 shows the effect of adding different amounts of
mitomycin C to poly[d(G-m5C)] under bifunctional activating
conditions. Figure 2(a) shows a typical c.d. spectrum of the B-
form of poly[d(G-m'C)] corresponding to the polynucleotide in
the absence of mitomycin, as well as the changes induced by the
drug at the added drug/nucleotide ratios indicated in the legend
to the Figure. At low added drug/DNA ratios (ra < 1) we
observe, in the 240-310 nM region, a B-form of poly[d(G-m5C)]
without a change in the c.d. spectra produced by the adduct-
induced c.d. which is superimposed on the c.d. of the polymer as
described for other DNAs [5,16,18], while at quite larger ratios of
added drug to DNA (ra> 1) the adduct-induced c.d. pheno-
menon becomes evident. This is characterized by a Z-like c.d.
spectrum [17]. In the 330-400 nm region, Figure 2, under both
B- and Z-buffer experimental conditions, the polynucleotide
shows no c.d. signal. In the presence of increased amounts of the
reduced mitomycin an extrinsic induced effect is observed in
this region outside the c.d. spectral range of poly[d(G-m5C)].
Although it is acknowledged that these positive bands outside
the polynuc}eotide region appear to reflect the presence of bound
ligand molecules [20], this interpretation is not so obvious for
mitomycin C, since at the region around 380 nm the drug alone
produces a clear c.d. band of relatively large magnitude [5]. The
presence of an isodichroic point at 373 nm (see Figure 2b) might
indicate that the DNA conformation changes somewhat after
drug binding. However, the binding to the Z-form of
poly[d(G-m5C)] described through the changes in the molar
ellipticity in the 370-380 nm region must be evaluated with
caution. These changes resemble those displayed by the mito-
mycin-B-form complex shown in Figure 2(a), indicating that the
drug is also associated in a non-covalent way to some regions in
both poly[d(G-m5C)] conformations, but only cross-linked to a
few regions which might remain in the B-form in the otherwise
Z-form polymer. It is known that mitomycin does not bind, for
example, to poly[d(G_BrC)] in the Z conformation [5], and
cytosine methylation could enhance mitomycin C cross-linking
in DNAs which are in the B conformation [21]. In any case, no
symptoms of a Z -+ B reversion induced by mitomycin are
observed in the 210-300 nm region in Figure 2(b).
31P-n.m.r. studies
To gain new insight into the meaning of the positive molar-
ellipticity changes at the 380 nm region and the Z plus mitomycin
spectra, as well as to check whether the drug could bind to the Z
conformer of poly[d(G-m5C)], we followed a different approach
unambiguously whether the Z-like spectra in Figure 2(a) are due
to Z-DNA or to the induced mitomycin c.d. spectrum [17]. It is
well known that 31P n.m.r. is a sensitive probe of the structure
and dynamics ofDNA fragments in solution [22]. An important
aspect is the sensitivity of phosphorous chemical shift to the
conformation of phosphodiester backbone [23]. The B and Z
conformers can easily be distinguished [24], and thus any
conformational change after cross-linking mitomycin C can be
unambiguously assigned to changes in the polynucleotides since
mitomycin lacks phosphorous atoms (see Figure 1). First of all,
we determined the chemical shifts of the sonicated poly[d(G-
m5C)] sample in the B and Z conformations (see Figures 3a and
3c). In all cases broad signals appeared, mainly due to the
transverse slow motion ofDNA fragments in water solution and
the broad range of DNA fragments produced by sonication
(about 150 bp long [24]) that produce similar, but not identical,
resonances. In the absence of magnesium (B-form), only one
signal appeared, centred at -4.25 p.p.m. (linewidth around
50 Hz), whereas in the presence of 3 mM MgCl2 (Z-form) two
signals appeared at -4.30 and -2.84 p.p.m. (linewidth around
100 Hz). These two resonances agree with those described
previously for Z-DNA [24] and can be assigned to the non-
equivalent g,g+ and t,g+ phosphodiester conformations in the
left-handed polymer [25].
New n.m.r. signals appeared when mitomycin was added to
poly[d(G-m5C)] under reductive bifunctional activating condi-
tions, at -1.56 p.p.m. in the case of the B-formation (Figure 3b),
and at - 1.53 and -0.33 p.p.m. in Buffer Z (Figure 3d). These
experimental facts are consistent with the results obtained using
other DNA cross-linking agents which, when associated to
DNA, make a downfield change in chemical shift of about
2 p.p.m. [26]. However, we observe these changes as narrow
singlets, while it is commonly accepted that the presence of
bonded drugs restricts the mobility of the DNA strands inducing
a notable increase in the linewidth [27]. At first glance the
presence of those sharp signals suggests that the drug which is
not cross-linked to the polynucleotide can interact through the
minor groove. This interaction produces a reversible complex
which might locally modify the phosphodiester backbone, leading
to similar local structures in both DNA conformers. Mitomycin
C shows a rather low affinity for DNA [28], and the drug added
to excess (Figure 3 and Table 1) must be involved in a continuous
exchange between bound and free ligand. It generates an ad-
ditional mechanism of relaxation at a few phosphorus atoms
which are close to the interacting sites in the minor groove of
poly[d(G-m5C)], thus rendering these sharp n.m.r. signals. The
presence of one additional signal under B-buffer conditions and
two under Z-form conditions (Figure 3) indicates that the drug
does not seem to induce large conformational changes in the
phosphodiester backbone. These well-defined signals also in-
dicate that the binding sites are well located, and there are no
transverse or rotational degrees of freedom. Another feature of
the n.m.r. spectra in Figures 3 and 5 (below) that merits further
consideration is the relative areas of the narrow and broad
signals under B- and Z-form conditions. Assuming that the
relative relaxation times of the two DNA conformers were
similar, and, therefore, the area under each peak was proportional
to the number of nuclei that originate the signal, the n.m.r.
spectra would indicate that the amount of cross-linked sites in B-
DNA is larger than for Z-DNA. The presence of mitomycin
binding to B-form poly[d(G-m5C)] clearly does not produce a
transition to Z-form DNA (Figure 3b), despite the characteristics
of the c.d. spectra in Figure 2(a). The changes in the c.d. spectra
might reflect the interaction between the chromophores of
using 31P n.m.r. This technique is also helpful to confirm mitomycin C and DNA through a mechanism similar to that
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Figure 3 Effects of bifunctionally activated mitomycin C on the 31P n.m.r. of sonicated poly[d(G-m5C)J
(a) 31P-n.m.r. spectrum of the B-form of the polynucleotide. (b) 31P-n.m.r. spectrum of the polynucleotide in the presence of bifunctionally activated mitomycin C (ra = 3). (c) 31P-n.m.r. spectrum
of the Z-form of the polynucleotide. (d) 31P-n.m.r. spectrum of the Z-form of the polynucleotide in the presence of bifunctionally activated mitomycin C (ra = 3).
originating the c.d. spectra of DNA by base-base exciton
coupling.
Non-covalent and covalent binding of mitomycin C
The results of the mitomycin effect on poly[d(G-m5C)] which had
been equilibrated previously in the Z-form merit further con-
sideration, since it is noteworthy that the c.d. and n.m.r. results
(Figures 2b and 3d) might indicate that mitomycin C binds to
poly[d(G-m5C)] in the Z-conformation. However, it may be the
case that it only binds to the regions which remain in B-form,
perhaps in an extension similar to the case of the polymer in the
B-conformation, but does not induce a detectable reversion to
the B-form. At first glance, the positive ellipticity in the c.d.
spectra around 370 nm, discussed above, and the appearance of
phosphorus n.m.r. signals at -0.33 and - 1.53 p.p.m. (Figure 3)
seem to confirm such a hypothesis. However, the experiments
displayed in Figures 2 and 3 were performed using samples
obtained by simply mixing the polynucleotide and drug under
the reductive bifunctional activating conditions described in [7],
so at this stage of the work no attempt was made to separate the
unbound drug. Therefore, in order to gain further insight into
the mitomycin effects on poly[d(G-m5C)] the samples used for
the n.m.r. experiments (displayed in Figures 3b and 3d) were
divided afterwards in two parts to confirm whether the results
discussed above could be a symptom of mitomycin binding to
both forms of the polynucleotide or rather due to the presence of
unbound drug. The different samples, four in total, were dialysed
against either Buffer B or Buffer Z respectively and their
drug/nucleotide binding ratios measured (see Table 1) and
analysed again using c.d. and 31P n.m.r.
When half of the sample of B-form polynucleotide plus
mitomycin (shown in Figure 3b) was dialysed against Buffer B,
the resulting c.d. spectrum was of a B-like form (Figure 4a, line
1), while the other half dialysed against Buffer Z displayed some
characteristics of the Z-DNA spectrum in the 260-280 nm region
(line 2 in Figure 4a) though with negative ellipticity in the 250 nm
region (a characteristic of the B-form spectrum). This may either
be taken as evidence of an intermediate form or simply be
produced by an induced CD onto the B-DNA spectrum due to the
drug-base electronic interactions [17].
Furthermore, when half of the sample of poly[d(G-m5C)] plus
mitomycin, in Buffer Z, used in the 31P-n.m.r. studies shown in
Figure 3(d), was dialysed extensively against Buffer B it rendered
a c.d. spectrum consistent with a B-form ofDNA (Figure 4b, line
1), but displayed a Z-like spectrum when the dialysis was made
against Buffer Z (Figure 4b, line 2). Interestingly, ifwe confidently
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Figure 4 C.d. ot sonicated poly[d(G-m5C)J_mitomycin complexes in the
absence of unbound drug
(a) The sample displayed in Figure 3(b) dialysed against Buffer B ( ) or Buffer Z
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Figure 5 31P-n.m.r. of a poly[d(G-m5C)]-mitomycin complex in the absence
of unbound drug
This corresponds to the sample whose c.d. spectrum is shown in Figure 4(b),
binds to the B-form, but not significantly to the Z-form, the
spectra should represent a clear example of an intermediate in a
B -* Z transition, with the drug bound to B-form polynucleotide
while other portions of the spectrum are in the Z conformation
owing to the presence of 3 mM MgCl2. The 31P-n.m.r. spectrum
(Figure 5) resembles the control Z-form one, with hardly
appreciable sharp signals at -0.33 and - 1.53 p.p.m., in agree-
ment with their relationship with the non-covalent bound mito-
mycin C. These results might suggest that mitomycin C can only
cross-link a few guanine bases in B domains within the Z-form
polymer.
DISCUSSION
In the present study we used c.d. and 31P-n.m.r. to characterize
the structure of poly[d(G-m5C)] modified by reductively activated
mitomycin C. C.d. spectra are widely used to measure the effect
of bound drug on the B Z transitions. In most cases the ligand
appears to work as an inhibitor of the B -. Z conformational
change and as allosteric effector of the Z -. B conformational
transition [12-15], favouring the B conformation. The cases of
Z -+ B reversion described previously [12-15, and references cited
therein] were obtained with drugs which bind reversibly to DNA,
except in a particular and enlightening case in which ethidium
was covalently bound to DNA [14]. At first glance, mitomycin C
should have an advantage when used to measure such a transition
in that the mitomycin bis-adduct is irreversible; thus we can be
sure that the drug is, for example, only bound to fragments in the
B-conformation, while other regions remain in the Z-confor-
mation.
Mitomycin binding to B-form poly[d(G-m5C)] does not pro-
duce a transition to Z-form DNA, as unambiguously established
by the 31P-n.m.r. experiments (Figure 3b), despite the character-
istics of the c.d. spectra in Figure 2(a), and in clear agreement
with the data obtained with other DNAs [5,17,18]. The results
described here corroborate the view that covalently attached
drugs might nucleate B-regions which remain irreversibly in this
conformation. These drugs, and many intercalating agents which
bind to DNA through the minor groove, appear to possess high
effectiveness as inhibitors of the B -+ Z transition [12-15]. In
contrast, it is remarkable that platinum anti-tumour drugs,
which cross-link DNA through the major groove [29], behave in
a different way, since they increase the Z-DNA content in
plasmids with G+ C-rich inserts [30].
The Z - B-form reversion in poly[d(G-C)] has been described
in the presence of bis-adducts of mitomycin C. This reversion
arises from the cross-linking of the drug to B-regions which
might exist in the overall Z-polynucleotide [5] followed by
stabilization of the B-form, producing the Z -- B conformational
change. The only explanation for the absence of a Z -+ B
conformational reversion in the experiments using poly[d(G-
m5C)] (Figures 2a, 3 and 5) is that the drug binds neither to
the Z-form of the polymer nor 'sufficiently' to the B-zones
within it, tentatively because the Z-form of this polymer is more
stable as a Z-form polynucleotide under low salt conditions and
behaves as a 'less-mobile' polymer (i.e., the cross-link produces
greater rigidity in the modified polynucleotide). Therefore,
poly[d(G-m5C)] is neither reverted to the B-form nor sufficiently
cross-linked by the bifunctionally activated mitomycin under Z-
forming conditions. Mitomycin C fits snugly into the minor
groove of Z-DNA, but its C-l and C-10 atoms (see Figure 1) are
not as close to the N-2 atoms of the polynucleotide as they are
in the B form [5-6], in which the minor groove can widen to
about 0.1 nm (10 A), facilitating the cross-link [6]. The binding
ratios displayed in Table 1 corroborate the view that mitomycin
only binds slightly to the small equilibrium fraction of B-form,
but is unable to induce the Z -+ B transition in poly[d(G-m5C)].
Moreover, the binding ratios of mitomycin to the B-conformer
of poly[d(G-m5C)] should be higher than for poly[d(G-C)] as is
the case (cf. Table 1 and [21]) and in agreement with the preferred
cross-linking of mitomycin C to methylated GpC tracts [21].
In summary, mitomycin C appears to inhibit the B -+ Z
transition of poly[d(G-m5C)], even in the presence of 3 mM
MgCl2, while neither the Z-form of poly[d(G-m5C)] nor the B-
like regions in the high-salt form of the polynucleotide interact
significantly with the drug under bifunctionally activating condi-
tions; thus no reversion from the Z-form to the B-form of the
polynucleotide can be observed under salt conditions which are
required for the Z-form to exist. As described in detail in the
Introduction, studies on methylated regions in DNA emphasize
the important role that B -. Z transitions might play in the
control of gene activity [9-11]. Studies like that presented here
not only give a clue to the possible mechanism of action of the
anti-tumour drug mitomycin C on guanine + cytosine regions in
DNA, but also offer additional information about the effect of
190 J. Portugal and F. J. Sanchez-Baeza
small ligands binding on DNA, thereby providing us with new
details about the nature and potential role of the Z and B
conformations of DNA.
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